Beyond Air, Inc. (NASDAQ: XAIR) announced that it has secured a national group purchasing agreement (GPA) with a U.S. group purchasing organization, effective April 1 2026. The new GPA adds to the company’s existing agreements with Vizient and Premier, Inc., and extends LungFit’s reach to nearly 2,000 U.S. hospitals and health systems under a single negotiated pricing structure.
The GPA is a key milestone in Beyond Air’s growth strategy. By channeling sales through a large GPO network, the company can streamline procurement for hospitals, accelerate adoption of its tankless nitric‑oxide platform, and generate recurring revenue from filters and service contracts. The agreement also positions LungFit for deeper penetration in the U.S. market, where the company’s existing 35‑country partnership network has already driven strong international growth.
LungFit’s Plasma Pulse Technology generates nitric oxide on demand from room air, eliminating the need for traditional gas cylinders. The platform has received FDA approval and CE Mark for treating term and near‑term neonates with hypoxic respiratory failure, and the company is exploring additional therapeutic applications such as ultra‑high concentration nitric oxide for solid tumors and neurological disorders.
Financially, Beyond Air has posted a 129% revenue increase over the last twelve months, but its gross profit margin remains low at 1.82%. In Q1 2026, revenue reached $1.8 million and the company reported a net loss of $7.7 million. The GPA is expected to bolster recurring revenue streams and help improve margin pressure over time.
CEO Robert Goodman noted that “Our GPO relationships play an important role in expanding access to LungFit PH, and this additional agreement meaningfully increases our reach.” The new GPA underscores the company’s focus on scaling its technology and expanding its commercial footprint in the U.S. market.
The agreement is expected to accelerate commercial adoption of LungFit, strengthen the company’s recurring revenue base, and support its broader strategy of expanding into new therapeutic areas while managing the challenges of thin gross margins.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.